Treatment of Alzheimer’s and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
Overview
Treating with measures that may improve metabolic functioning of neurons in an integrated protocol
Full Title of Study: “Effective Treatment of Alzheimer’s and Dementia With the MIND Protocol”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: December 2017
Detailed Description
Most organ failure results in modest drops in function until over 50% of function is lost. At a certain point, even modest drops in physiologic activity result in dramatic drops in clinical function. Though less homogeneous than in other organs, clinical experience and the literature suggests a similar process occurs in the brain. The hypothesis is that by using an integrated protocol to, essentially, "tune up" neuronal function, a 5-10 % improvement in metabolic functioning may translate to significant improvement in clinical functioning. This tune-up will include "MIND": M- Metabolism– optimizing hormonal function I- Infections– looking for and eliminating N- Nutritional and herbal support D- Drugs- Weaning subjects off unneeded medications
Interventions
- Other: A mix of natural treatments and medications
Arms, Groups and Cohorts
- Experimental: Treatment with MIND
Clinical Trial Outcome Measures
Primary Measures
- Montreal Cognitive Assessment (MoCA)
- Time Frame: 6 months
- Looking to see what percent of patients show improvement
Secondary Measures
- Mini Mental Status Exam (MMSE)
- Time Frame: 6 months
- Alzheimer’s Disease Assessment Scale- Activities of Daily Living (ADAS-ADL)
- Time Frame: 6 months
Participating in This Clinical Trial
Inclusion Criteria
- A diagnosis of Alzheimer's and/or dementia with an MMSE score over 12 or being ambulatory and able to travel outside the home with assistance. – Must have a caregiver living with them. Exclusion Criteria:
- Overt progressive and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness. – Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Practitioners Alliance Network
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.